A phase Ib/II study of copanlisib in combination with cetuximab in HNSCC patients harboring a PI3KCA mutation/amplification and/or a PTEN loss is currently ongoing (NCT02822482). This evidence concerns the gene PTEN and head and neck squamous cell carcinoma.